About
Helical, founded in 2024 in Luxembourg, converts biological AI foundation models into reproducible drug discovery workflows for pharmaceutical teams.
Technology & BusinessWhat · How · Which stage
Research Areas生命科学生物MediumEvidence
将生物AI基础模型转化为制药团队可复现的药物发现工作流
Source：Official site · Updated 2026-09-10 · View source
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 12
Founders / team· 1
Funding history
- 2026-04Seed$10M
Investors · Redalpine, Gradient Ventures, BoxGroup, Frst CapitalSource · SVTR Weekly #153 ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M
United States
BusinessLatest roundTotal raisedDate- Network Bio
Links leading US academic biobanks into a unified research network producing training-ready multimodal datasets, and trains disease-specific AI foundation models on them that transfer across diseases, for disease detection, biomarker discovery and drug development
Undisclosed · $50M · 2026-08
$50M - Noetik
AI-based drug discovery, cancer immunology
Seed · $14M · 2023-09
$14M - Onepot
Small-molecule synthesis for drug discovery for biopharma companies (AI + automated synthesis)
Seed · $13M · 2025-11
$13M
China
BusinessLatest roundTotal raisedDate- LattixOrigin
Cross-scale human brain foundation model for drug target discovery in neurodegenerative diseases
Seed · 2026-10
— - MindRank
Designs and develops novel small-molecule drugs using its in-house AI drug discovery platform MAP
Series B · $52M · 2026-07
$52M - AIPher
AI-native drug discovery: proprietary drug foundation models and AI agent engine for early discovery of novel small-molecule, peptide and other drugs
Angel · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Cyclana Bio
Tissue-level drug discovery model for treating endometriosis
Pre-Seed · $7M · 2025-10
$7M - Bio Protocol
Funds and accelerates drug discovery through decentralized research agents
Seed · $7M · 2025-09
$7M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Miles Wang 新公司
Develops AI models for drug discovery
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 11 at a nearby stage
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.